Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Anticoagulants

Direct oral anticoagulants carry lower risk of major bleeding versus warfarin, data show

Research from primary care suggests apixaban may be the safest of the direct oral anticoagulants overall.

Direct oral anticoagulants (DOACs), particularly apixaban, are associated with a reduced risk of major bleeding compared with warfarin, real-world data from primary care in the UK show.

A study published in the BMJ (4 July 2018) used data on 103,270 patients with atrial fibrillation (AF) and 92,791 patients without AF who received warfarin, rivaroxaban or apixaban to examine the risk of major bleeding and death[1].

Compared with warfarin, the researchers found that apixaban reduced the risk of major bleeding in both people with AF (hazard ratio [HR]: 0.66) and without AF (HR: 0.60). Dabigatran was associated with a decreased risk of intracranial bleeding in people with AF (HR: 0.45), as was rivaroxaban in those without AF (HR: 0.54). However, rivaroxaban and lower doses of apixaban were associated with increased all-cause mortality in people with and without AF.

The researchers said the findings suggested that apixaban may overall be the safest of the new anticoagulant class.

“Our results give an initial, reassuring indication of the risk patterns for all patients taking anticoagulants, in particular with respect to those prescribed apixaban,” they said. 

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205305

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Apixaban molecular structure

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.